ADA: GLP-1 Receptor Agonist Use Beneficial in Adults With Obesity, Autoimmune Disease MONDAY, June 8, 2026 -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
And as I mentioned, the results were stunning
December 2, 2024 The lawsuit involving Ozempic and other GLP-1 weight loss drugs centers on claims that these medications have led to severe gastrointestinal side effects, including gastroparesis, nausea, and vomiting
When you see it worked for other people and it doesnt work for you, it makes you depressed
The platform integrates over 500 million patents, scientific publications, clinical trial records, and market intelligence sources through a proprietary R&D ontology purpose-built for technology scouting and competitive analysis
Summary: Ozempic does not contain venom